

COVAX

CEPI



unicef



COVAX Allocation Round 16

Vaccine Allocation Decision Proposal

June 22, 2022

Table of Contents

Round Background

- ☐ Introduction
- ☐ Round Participant Scope and Overview
- ☐ Round Demand Overview
- ☐ Round Supply Overview
- ☐ Overview of Methodology

Round Proposal

- ☐ Round Outcome
- ☐ Overview Graphs
- ☐ Next Steps & Signatures

Annexes

- ☐ Policy Updates
- ☐ Round Demand Methodology
- ☐ Round Supply Methodology
- ☐ Additional Allocations

Round Background

Introduction

Context for COVAX Allocation Round 16

- COVAX Allocation Round 16 (R16) is the second allocation round of Phase 2, focusing on meeting the demand expressed by AMC (Advance Market Commitment) participants in line with their national targets.
- This round covers a four-month period, from July to October 2022 (inclusive). Similarly to Allocation Round 15 (R15), and as per Phase 2 principles, APA (Advance Purchase Agreement) doses and donated doses are jointly allocated in R16.
- Demand planning covered the 6 months of May through October. R16 covers the four months of July to October. Allocations for the two initial months of May and June were processed separately as urgent allocations (see slide 22).
- Since R15 allocation covered demand for April to September 2022, R16 overlapped for the months of July to Sept to meet additional demand for those same months, with the addition of Oct. Hence R16 covers the entirety of the Oct demand, while covering partly the July to Sept demand. Urgent Allocations between R15 and R16 (see slide 22) and Paediatric Allocations (see slide 21) additionally met Participants' demand for the same demand period.

Eligible participants (AMC)	R16 Demand (original request)	R16 Supply available (snapshot)
91 ¹	57,499,181	500.3m ²

- Detailed information on methodology, policy and programmatic decisions that were considered for this round are available in the Annexes and referenced as needed in this VAD.
- Information on previous COVAX allocation rounds are available on the WHO website ([web link](#)).

1. Number of countries is AMC 92 excluding India, whose doses are allocated in a separate process – see slide 4.

2. This number represents a snapshot of the supply available for both the urgent allocation process and Round 16 at a given moment in May 2022. Due to the inherent dynamics of supply, this number is undergoing continuous change..

Round Participant Scope and Overview

Participant Scope

COVAX Facility Participants

- Only AMC participants are allocated doses under Phase 2.
- There are 92 Advance Market Commitment (AMC) Participants. India's allocations are now handled through a different process. Thus, in principle, the Facility conducts allocation Rounds for the remaining 91 AMC participants.

Round Participants

- Participants' demand was gathered through the COVAX demand planning process. This includes monthly demand, by product, based on participants' national targets and plans. The demand data was frozen on 9 May 14.00 CET.

Of the 91 AMC participants:

3 participants are not included in Round 16 since they have opted out of COVAX or have no vaccination programs currently in place.

88 participants were eligible for Round 16, of whom 36 received an allocation.

52 participants did not express demand for COVAX allocation for this round, and were therefore not allocated any doses during Round 16 ¹.

- **Product preference** was based on demand plans submitted by participants. In case of shortage of products, and in the absence of alternatives in the demand plan, the Facility based the allocation on preference information from the COVAX Collaboration Platform (deadline for changes was 29 April 2022).
- Like in Round 15, an additional 15% was allocated to all Participants receiving an allocation to allow for additional needs and/or boosters (with exception of Pfizer doses, given that Pfizer allocations in prior rounds already took all needs into account).
- **No coverage caps were applied in Round 16** (like in Round 15).


1. Many of these had been allocated doses in Allocation Round 15 that covered up until September 2022.

Round Demand Overview

Overview of Total demand for R16

Total participant demand for products expressed in Round 16 (for July through October 2022): 62.3 million

Product	Initial demand (M)	Effective demand ¹ (M)
AstraZeneca - Vaxzevria	9.8	11.3
Janssen - Ad26.COV 2-S	9.6	11.1
Moderna - mRNA-1273	0.9	1.0
Pfizer - BioNTech – Comirnaty ² .	25.7	25.7
Sinovac	10.4	11.9
SII – COVISHIELD	0.1	0.1
Sinopharm	1.1	1.3
SII – Covovax	0	0
Total (rounded)	57.5	62.3



1. Initial demand plus 15% top-up

2. The 15% top-up was not added to Pfizer demand

Round Supply Overview

Round Supply - Overview

COVAX Allocation Round 16

- Supply from donations and APA was pooled in accordance with Phase 2 principles. A total of 7 products were available for R16. Total supply available for allocation exceeds demand.
- In principle, doses of shelf life >16 weeks at the time of the offer letter are allocated through the round, while doses of shorter shelf life are excluded and/or handled in the separate process, as appropriate.
- Some products had minimal or no supply availability. Participants requesting those products were compensated with alternate products eligible for them.

Products	Total supply allocated (doses)	R16 Allocation of Total Product-Specific Supply	Minimum Shipment Size (doses)
SII - Covishield	162,000	All eligible ² supply used	18,000
SII - Covovax	8,028,000	Partially used	12,000
Janssen – Ad26.COV 2-S	14,860,800	Partially used	7,200
Pfizer BioNTech - Comirnaty	37,590,030	Partially used	1,170 (PBS) or 2,880 (RTU) ¹ .
Sinopharm	1,339,200	All supply used	3,600
Sinovac	32,400	All supply used	1,200
Moderna	574,560	All eligible ² supply used	10,080
Total	62,586,990	~500m	

Total doses allocated in R16 = 62,586,990

- 28% APA
- 72% Donations

The supply/demand data presented in this report was gathered 4 weeks ago and, as such, is a snapshot of the demand/supply landscape at that point in time:

- Supply is shifting by the potential to activate a phasing process and by the dynamics inherent to the dose-sharing process
- Demand figures are preliminary and shifting as several factors can modify them in the visible future, including demand for boosters, uncertainty around new variants and an optimal schedule of 3-dose regimen, among others
- The supply-demand balance is moving on a real-time basis and figures will be updated on a regular cadence. Significant mitigation actions that have dramatically reduced this difference have been pursued

1. RTU formulation applicable to some countries..

2. Eligible supply refers to supply with adequate shelf life.

Round Supply Overview - Donations

Round Supply Considerations – Donated Doses

- In alignment with Phase 2 principles, the COVAX Facility has included confirmed donations in addition to APA supply. Round 16 has allocated doses from 17 donating countries.

Overview of Donation Supply Available in R16

Product	Donors	Donor earmarking
Janssen – Ad26.COV 2-S	Austria, Czechia, France, Ireland, Italy, Lithuania, Portugal, Slovakia, Slovenia, Sweden, United Kingdom	• All participants
Moderna – mRNA-1273	Belgium	• All participants
Pfizer BioNTech - Comirnaty	Belgium, European Country Group, France, Italy, Ireland, Netherlands, Spain, Sweden, Switzerland, United States of America	• All participants

Overview of Methodology

Allocation Methodology for R16

- As in R15, and based on Phase 2 allocation principles and objectives, R16 aims to allocate doses according to participants' product requests and, if this is not possible, to meet their designated alternate products, giving priority to lower coverage countries.
- The **main steps of the methodology** are described below¹:
 1. Participants are ranked by coverage in ascending order
 2. The allocation of the first month's supply (in this case July) takes place respecting the following order:
 - i. The requested products are the first to be allocated up to participant demand, provided there is sufficient supply
 - ii. If supply is not sufficient to meet the products requested, the methodology resorts to the participant's demand plan to identify substitute products to meet the demand. In the absence of this information, product preferences are extracted from the COVAX Collaboration Platform (CCP) and the participant's demand is met with "highly desirable" or "desirable" products.
 3. Step 2 is repeated for each month through and including October 2022²:
 4. An additional 15% supply is allocated to countries by repeating Steps 2 and 3 above:
 - i. The 15% is offered as a percentage of each of the products that the participant has requested, except Pfizer (see slide 4).
 - ii. Unmet volumes against this additional 15% due to insufficient supply is met with substitute products in the same way as delineated above.

¹ Supply needed to satisfy demand for May and June is defined and subtracted from the overall available supply for R16.

² The rationale behind offering this additional supply is to allow Participants to meet dynamic needs, such as boosters, while respecting Participants' preferences. The 15% figure is chosen based on participants' feedback during bilateral discussions with country-facing staff.

Round Proposal

Round Outcome

Key Figures for COVAX Allocation Round 16



Demand and product preference information

- 100% of the participants have received the number of doses they requested.
- Out of the 57.5m doses requested by participants, approximately 36.6m doses (63%) were allocated with the requested product.
- For the remaining 20.9m doses requested by participants, the specific products were allocated using the information available in participants' demand plans.
- An additional ~5m doses were offered to all participants as the additional 15%.

Total doses allocated



Total doses allocated in R16 = 62,586,990

- 28% APA
- 72% Donations

Allocation snapshot

Product	Total allocated ¹
SII – COVISHIELD	162,000
SII – Covovax	8,028,000
Janssen – Ad26.COV 2-S	14,860,800
Moderna – mRNA-1273	574,560
Pfizer BioNTech - Comirnaty	37,590,030
Sinopharm	1,339,200
Sinovac	32,400
Total	62,586,990

1. Rounded up figures due to batch sizes.

Round Outcome - Allocations by Participant (1 of 4 slides)

Participant Name (in alphabetical order)	WHO Region	SII- COVISHIELD	SII-COVOVAX	Janssen- Ad26.COV 2-S	Moderna- mRNA-1273	Pfizer BioNTech - Comirnaty	Wuhan CNBG – Inactivated (Sinopharm)	Sinovac	Total R16 doses	Population Covered* (%)
Afghanistan	EMRO			691,200					691,200	22.6%
Algeria	EMRO			475,200					475,200	60.7%
Angola	AFRO									77.0%
Bangladesh	SEARO									175.3%
Benin	AFRO									48.4%
Bhutan	SEARO					51,480			51,480	145.2%
Bolivia	PAHO									115.7%
Burkina Faso	AFRO									45.7%
Cabo Verde	AFRO									126.9%
Cambodia	WPRO					788,580			788,580	146.1%
Cameroon	AFRO									30.4%
Central African Republic	AFRO									51.5%
Chad	AFRO			3,758,400		345,150			4,103,550	67.3%
Comoros	AFRO									84.4%
Congo	AFRO									58.1%
Côte d'Ivoire	AFRO					993,600			993,600	65.2%
Democratic Republic of the Congo	AFRO									35.1%
Djibouti	EMRO									126.6%
Dominica	PAHO									159.2%
Egypt	EMRO									109.0%
El Salvador	PAHO					403,650			403,650	120.1%

* «Population covered» is the fraction of the population with a hypothetical 2-dose coverage (all sources of supply considered) after Round 16 allocation and including the doses shipped in previous rounds.

Round Outcome - Allocations by Participant (2 of 4 slides)

Participant Name (in alphabetical order)	WHO Region	SII- COVISHIELD	SII- COVOVAX	Janssen- Ad26.COV 2-S	Moderna -mRNA- 1273	Pfizer BioNTech - Comirnaty	Wuhan CNBG – Inactivated (Sinopharm)	Sinovac	Total R16 doses	Population Covered* (%)
Eswatini	AFRO									51.2%
Ethiopia	AFRO									51.0%
Fiji	WPRO									105.8%
Gambia	AFRO									41.7%
Ghana	AFRO					87,750			87,750	77.2%
Grenada	WPRO									78.8%
Guinea	AFRO						738,000		738,000	69.2%
Guinea-Bissau	AFRO			100,800					100,800	61.5%
Guyana	WPRO					126,360			126,360	78.4%
Haiti	WPRO									5.9%
Honduras	WPRO					552,240			552,240	89.4%
Indonesia	SEARO		8,028,000					32,400	8,060,400	104.0%
Kenya	AFRO									61.7%
Kiribati	WPRO					63,360			63,360	127.5%
Kosovo (in accordance with UN Security Council resolution 1244 (1999))	EURO									95.3%
Kyrgyzstan	EURO					150,930			150,930	43.2%
Lao People's Democratic Republic	WPRO				504,000		75,600		579,600	114.4%
Lesotho	AFRO			115,200					115,200	80.4%
Liberia	AFRO									58.0%
Madagascar	AFRO									40.1%
Malawi	AFRO									64.7%
Maldives	SEARO					101,790			101,790	182.7%

* «Population covered» is the fraction of the population with a hypothetical 2-dose coverage (all sources of supply considered) after Round 16 allocation and including the doses shipped in previous rounds.

Round Outcome - Allocations by Participant (3 of 4 slides)

Participant Name (in alphabetical order)	WHO Region	SII- COVISHIELD	SII- COVOVAX	Janssen- Ad26.COV 2-S	Moderna -mRNA- 1273	Pfizer BioNTech - Comirnaty	Wuhan CNBG – Inactivated (Sinopharm)	Sinovac	Total R16 doses	Population Covered* (%)
Mali	AFRO			1,008,000			518,400		1,526,400	42.7%
Mauritania	AFRO	162,000		446,400		101,790			710,190	79.9%
Micronesia (Federated States of)	WPRO									53.4%
Mongolia	WPRO									102.2%
Morocco	EMRO									123.7%
Mozambique	AFRO									101.7%
Nepal	SEARO									105.9%
Nicaragua	PAHO					2,001,690			2,001,690	111.6%
Niger	AFRO									35.6%
Nigeria	AFRO									47.9%
West Bank and Gaza	EMRO									108.9%
Pakistan	EMRO									65.7%
Papua New Guinea	WPRO			43,200			7,200		50,400	7.0%
Philippines	WPRO					26,563,680			26,563,680	138.0%
Republic of Moldova	EURO			187,200		101,790			288,990	50.2%
Rwanda	AFRO									108.2%
Saint Lucia	PAHO									76.3%
Saint Vincent and the Grenadines	PAHO					12,870			12,870	110.2%
Samoa	WPRO					71,370			71,370	135.7%
Sao Tome and Principe	AFRO									112.8%
Senegal	AFRO									56.3%

* «Population covered» is the fraction of the population with a hypothetical 2-dose coverage (all sources of supply considered) after Round 16 allocation and including the doses shipped in previous rounds.

Round Outcome - Allocations by Participant (4 of 4 slides)


Participant Name (in alphabetical order)	WHO Region	SII-COVISHIELD	SII-COVOVAX	Janssen- Ad26.COV 2-S	Moderna- mRNA-1273	Pfizer BioNTech - Comirnaty	Wuhan CNBG – Inactivated (Sinopharm)	Sinovac	Total R16 doses	Population Covered* (%)
Sierra Leone	AFRO			662,400		201,240			863,640	60.5%
Solomon Islands	WPRO									46.0%
Somalia	EMRO									53.9%
South Sudan	AFRO									38.4%
Sri Lanka	SEARO									91.4%
Sudan	EMRO									44.3%
Syrian Arab Republic	EMRO			4,953,600					4,953,600	41.4%
Tajikistan	EURO					797,940			797,940	76.4%
Timor-Leste	WPRO									56.0%
Togo	AFRO									64.3%
Tonga	WPRO									123.4%
Tunisia	EMRO					101,790			101,790	100.5%
Tuvalu	WPRO					2,340			2,340	72.0%
Uganda	AFRO					3,968,640			3,968,640	87.5%
Ukraine	EURO									66.1%
United Republic of Tanzania	AFRO			1,281,600					1,281,600	38.2%
Uzbekistan	EURO									79.4%
Vanuatu	WPRO				70,560				70,560	77.7%
Viet Nam	WPRO									139.2%
Yemen	EMRO			158,400					158,400	4.2%
Zambia	AFRO			979,200					979,200	74.1%
Zimbabwe	AFRO									73.4%

* «Population covered» is the fraction of the population with a hypothetical 2-dose coverage (all sources of supply considered) after Round 16 allocation and including the doses shipped in previous rounds.

COVAX has allocated 1.9 billion doses and shipped 1.5 billion doses to 145 Participants to date in 16 allocation rounds

As of 1st June 2022

Doses allocated to date by COVAX¹ (excl. cost sharing), Millions



1.9 Billion doses allocated¹

1.5 Billion doses shipped

16 Allocation rounds

145 Participants received shipments

1. Figure may be lower than previously published due to rejections of doses by Participants in Round 15

Round 16 lifted 2 participants over 40% and 2 participants over 70% coverage


MAY 16TH COVAX DATA / MAY 3RD GMA DATA / MAY 16TH STOCK DATA

■ Two-doses vaccinated equivalent¹, in country stock² (2DE³), COVAX and cost-sharing doses allocated, not shipped (2DE), Non-COVAX doses⁴ (2DE)

■ Round 15 Allocation (2DE)

Projected supply available per participant, expressed as 2-dose population coverage, including: two-doses vaccinated equivalent, in country stock, doses allocated through COVAX (R1-16, donations, reallocations), cost-sharing, and other sources of supply projected by end of Q4 2022 (n=88⁵)

2-dose supply population coverage, % sorted descending



- Round 16 allocated doses to all Participants according to their demand without caps
- 62.3 million doses were allocated, of which:
 - 14% (8.7 million) of doses went to participants with supply below 40%
 - 26% (16.5 million) were allocated to participants with supply below 70%
- 565 million doses are needed for all AMC91 countries to get to 70%⁶
- 88 million doses are needed for all AMC91 countries to get to 40%⁶

1. Estimated by total doses administered divided by 2 (assumes 2-dose regimen) ; 2. Doses received including GMA, with a deduction of administered doses and a 10% wastage of total doses; 3. Two-doses equivalent; 4. Other sources of supply include bilateral deals, multilateral supply (including AVAT), donations, and domestic production until end of Q4 2022 (GMA data); a pro-rated proportion of Q2 non-COVAX supply is assumed to be already shipped and is excluded to avoid overlap with in-country stock data; 5 AMC 91 excluding countries not participating in COVAX: Eritrea, Burundi and Marshall Islands 6. Figures before R16; figures may have changed upward since last IAVG report due to adjusted forecasting for Q3 and Q4 2022

Annexes

Policy Updates (1 of 2 slides)

Context for COVAX Allocation Round 16

Updates and Considerations for Round 16 and beyond

Consideration for participants coverage in COVAX allocations

- In January 2022, SAGE updated its Roadmap on prioritizing the use of Covid-19 vaccines. In accordance with the updated recommendation, the COVAX Facility removed the coverage cap of '70% from all sources.
- Since R15, all AMC participants can request doses to meet their individual coverage targets, including boosters for individuals above 12 years of age.

COVAX policy and updates on paediatric doses

- The COVAX Facility has an interim policy in place to respond to high coverage participants requests for paediatric doses, allocating vaccines to participants for children 5-11 years of age.
- As per the latest WHO prioritisation roadmap, children and adolescents with co-morbidities are in the medium priority-use group, and healthy children and adolescents in the lowest-priority use group. SAGE recommends that countries prioritise highest and high priority use groups for delivery of primary series and booster - such as older adults, health workers, immunocompromised, adults with comorbidities, pregnant persons, teachers & essential workers, and disadvantaged sociodemographic populations – ahead of medium and lowest priority-use groups.
- Participants who submitted demand were assessed against the following criteria: 1) Pfizer-eligible AMC participants with > 40% COVID-19 vaccine primary series coverage*; 2) proactively expressed demand for paediatric doses; 3) made progress towards meeting the priorities according to the WHO SAGE prioritization roadmap; 4) shown ability and intention to continue to deliver other vaccines through Routine Immunization.
- Total of 23,107,200 Pfizer paediatric doses were allocated to participants (see slide 21 for details).

Policy Updates (2 of 2 slides)

Context for COVAX Allocation Round 16

Updates and Considerations for Round 16 and beyond

Humanitarian Buffer

- In light of Phase 2 and the intent to meet real-time demand, COVAX has revisited the approach for allocating doses to the Humanitarian Buffer (HB). Since R15, COVAX relies on rolling allocations to the HB and only allocates doses for confirmed demand (approved applications) made to the HB up to the total of 5% of all allocated AMC doses. The demand will be assessed monthly, to coincide with each allocation round, and supply will be allocated based on that information.
- Given that the HB demand from prior rounds has been met, and there are currently no further applications under review, there is no allocation to the HB under R16.

COVAX Urgent/Additional Allocation Process

- An urgent/additional allocation process was designed to allocate doses in response to demand expressed in an ad-hoc fashion. This process was used for allocations that cover the demand expressed for May and June 2022. For additional details please see slide 22.

COVAX position on additional boosters (beyond the first booster dose)

- COVAX will aim to meet demand for additional booster doses for highest risk groups, specifically older adults, healthcare workers, and immunocompromised individuals.
- In line with the interim SAGE guidance, COVAX will provide mRNA vaccines as the additional booster dose but will consider countries' requests for alternative vaccines.
- Short-term benefits of administering booster doses to highest-risk groups, along with the fact that there is limited data to draw decisive conclusions about the benefits for healthy younger populations and about the duration of protection, suggests that countries consider the financial and opportunity cost of delivery of such programmes.
- COVAX advises participants to include demand for additional boosters in their demand planning and forecasts requests.

Additional Allocations – Paediatric Allocations

Participant	Product	Doses Allocated
Bangladesh	Pfizer BioNTech - Comirnaty	11,001,600
Bhutan	Pfizer BioNTech - Comirnaty	33,600
Cabo Verde	Pfizer BioNTech - Comirnaty	52,800
El Salvador	Pfizer BioNTech - Comirnaty	504,000
Grenada	Pfizer BioNTech - Comirnaty	4,800
Guyana	Pfizer BioNTech - Comirnaty	52,800
Honduras	Pfizer BioNTech - Comirnaty	153,600
Kosovo	Pfizer BioNTech - Comirnaty	4,800
Lao People's Democratic Republic	Pfizer BioNTech - Comirnaty	427,200
Mongolia	Pfizer BioNTech - Comirnaty	302,400
Nepal	Pfizer BioNTech - Comirnaty	8,395,200
Nicaragua	Pfizer BioNTech - Comirnaty	1,401,600
West Bank and Gaza	Pfizer BioNTech - Comirnaty	52,800
Rwanda	Pfizer BioNTech - Comirnaty	504,000
Saint Vincent & the Grenadines	Pfizer BioNTech - Comirnaty	4,800
St Lucia	Pfizer BioNTech - Comirnaty	9,600
Uzbekistan	Pfizer BioNTech - Comirnaty	201,600
Total		23,107,200

Additional Allocations – Urgent/Additional Allocations for May and June¹

Country	Product	Doses Allocated
Chad	Janssen – Ad26. COV 2-S	14,400
		14,400
		1,872,000
		936,000
	Pfizer BioNTech - Corminaty	1,510,110
Guyana	Pfizer BioNTech - Corminaty	1,170
		1,170
		1,170
		19,890
		26,910
Liberia	Janssen – Ad26. COV 2-S	295,200
		583,200
		612,000
Ethiopia	SII - Covishield	2,016,000
Tanzania	Janssen – Ad26. COV 2-S	2,632,800
		17,000
		1,757,500
	Pfizer BioNTech - Corminaty	400,140
Zambia	Janssen – Ad26. COV 2-S	4,500,000
Ukraine	Janssen – Ad26. COV 2-S	201,600
Total		17,412,660

1. These additional allocations were done between R15 and R16.

COVAX

CEPI



Thank you